Diabetes mellitus, a metabolic disorder, is characterized by hyperglycemia, altered metabolism of lipids, carbohydrates and proteins with an increased risk of complication of vascular diseases.¹,² The minimum defining characteristic feature to identify diabetes mellitus is chronic and substantiated elevation of circulating glucose concentration.²,³ Diabetes mellitus may present as a relatively sudden, potentially lethal metabolic catastrophe or it can be associated with few if any, symptoms or signs and may escape detection for many years. These extremes of clinical manifestations constitute the basis for subdividing diabetes mellitus into the insulin dependent (IDDM) and the non insulin dependent (NIDDM) types.

In the recent past the term IDDM has been replaced by Type 1 diabetes mellitus. Type 1 diabetic patients have β cell destruction, which is usually immune-mediated; the majority of the patients develop absolute insulin deficiency and are ketosis prone. The term NIDDM has been replaced by Type 2 diabetes mellitus, which encompasses the most prevalent form of the disease. Most patients in Type 2 diabetes mellitus exhibit insulin resistance and ultimately develop concomitant insulin secretory defect.²

Type 1 diabetes mellitus results from a severe absolute lack of insulin, caused by reduction in the β cell mass. The three interlocking mechanisms responsible for the islet cell destruction are genetic susceptibility, acute auto immunity and environmental insult.¹,²

Type 2 diabetes mellitus identifies patients who do not require insulin treatment to remain alive. The two metabolic defects characterizing Type 2 diabetes mellitus are 1. derangement of insulin secretion that is delayed or is insufficient relative to glucose load and 2. inability of peripheral tissues to respond to insulin – called insulin resistance. Though the primacy of one or the other of these defects is a matter of debate, most of the patients have relative or absolute deficiency of insulin.¹

Animal models of Type 2 diabetes mellitus

1. Genetic and spontaneous models
Spontaneous animal models of Type 2 diabetes mellitus are highly heterogeneous. At one end of the spectrum there is a mild hyperglycemia associated with obesity and
hyperinsulinemia. At the other extreme, animal models of Type 2 diabetes mellitus can develop a severe form of diabetes mellitus with extensive β cell degeneration, occasionally resulting in ketosis and the requirement of exogenous insulin to sustain life.¹

**Sand rat** (Psammomys obesus) is a model of nutritionally-induced Type 2 diabetes mellitus. Psammomys is prone to developing hyperinsulinemia, hyperglycemia and obesity when transferred to a high-energy diet, also primary insulin resistance is a species characterization of Psammomys. However, the potential to become diabetic decreases with age. In Psammomys of ages 1–12 months, maintained on a low-energy diet from weaning and transferred at different ages to a high-energy diet,² the sensitivity to the development of diabetes mellitus increases from weaning to a peak of about 5 months of age and decreases thereafter.

The fatty Zucker (Zucker diabetic fatty (ZDF) rat has been valued as a model of obesity, as the characteristics of the model are described as hyperglycemia, early hyperinsulinemia, fasting hyperglycemia, abnormal glucose tolerance, hyperlipidemia, mild hypertension. The ZDF rat carries the Lep mutation, which is typically referred to as just fa.³

The JCR: LA-Gp rat is a rodent model possessing insulin resistance, obesity, hypertriglyceridemia, including end stage cardiovascular diseases. This genetic model possesses the autosomal recessive gene called cp (corpulent), however, the elements that lead to the cardiovascular disease in this model are unknown.⁵

Metabolic syndrome X consists of insulin resistance as a primary defect associated with compensatory hyperinsulinemia, impaired glucose tolerance, dyslipidemia and hypertension.⁶ The obese spontaneously hypertensive rat (SHORB) is considered as a model of metabolic syndrome X. The obese phenotype results from a mutation of leptin receptor designated fa.⁴ SHORB is a useful model to understand the interaction of the various metabolic abnormalities that make up syndrome X.⁷

The obesity mutations in the mouse ob (obese) and db (diabetic) are mutation in the leptin structural gene (ob) and mutation in the leptin receptor gene (db). The obese hyperglycemic syndrome displayed by these mice shows various similarities to the metabolic abnormalities present in syndrome X and Type 2 diabetes mellitus. Insulin resistance, inappropriate hyperglycemia, impaired glucose tolerance as well as increased insulin secretion finally leading to β cell cell exhaustion are seen in these models. However, age, gender, and maintenance conditions are reported to affect the phenotype of these mice.⁸

The spontaneously diabetic KK mice are reported to have moderate obesity, polyphagia, polyurea, persistent glycosuria, glucose intolerance, moderate hyperglycemia, hyperlipidemia, insulin resistance of peripheral tissues and hyperinsulinemia. The diabetic characteristics of KK mice and the variant KKV are reverted to normal after 40 weeks of age.⁹

The OLETF (Otsuka – Long - Evans – Tokushima – Fatty) rat is a spontaneously diabetic rat with characteristic features of late onset hyperglycemia (after 18 weeks of age), a chronic disease state, increased urinary protein excretion, higher glomerular filtratin rate, increased kidney weight etc. Thus the clinical and pathological features of the disease state in OLTEF rats resemble those of human renal complications in human Type 2 diabetes mellitus.¹⁰

**The Cohen diabetic rat** is an exceptional, genetically derived, diet-induced Type 2 diabetes mellitus model that expresses genetic susceptibility to a carbohydrate-rich diet, a central feature of Type 2 diabetes mellitus in humans. A major drawback of this model is that it had never been systematically characterized in terms of phenotype or genotype, resulting in only limited recognition of its value and potential contribution to diabetes research.¹¹

2. Experimentally-induced models

Experimental Type 2 diabetes mellitus can be induced by: 1. Chemical destruction or surgical removal of part of the β cell mass, 2. Lesioning the ventromedial hypothalamus, 3. Feeding with high-fat and high-sugar diets 4. Malnutrition in utero, 5. High doses of counter-regulating hormones, particularly glucocorticoids and 6. Prolonged cell exposure to hyperinsulinemia.¹²

Type 2 diabetes mellitus induced by streptozotocin (STZ): Streptozotocin is a deoxy-s ([methyl-nitrosourea] carbonyl)-aminol-D gluco pyranose molecule that produces a selective toxic effect on β cells and induces diabetes mellitus in most laboratory animals.¹²,¹³ High doses of β cell toxins like streptozotocin and alloxan induce insulin deficiency and Type 1 diabetes mellitus with ketosis. However, doses calculated to cause a partial destruction of β cell mass can be used to produce a mild insulin deficient state of Type 2 diabetes mellitus, without a tendency to cause ketosis.¹³ The dosage is difficult to judge to create stable Type 2 diabetes mellitus without either gradual recovery or deterioration into Type 1 diabetes mellitus. Streptozotocin is preferred because it has more specific β cell cytotoxicity, but the sensitivity of this agent varies with species, strain, sex and nutritional state and there are batch differences in activity.¹⁵ The Okamoto rat model is a model for β cell damage and the prevention of the damage was based on results obtained in rodents with STZ and alloxan-induced diabetes mellitus.¹⁶ Recently, a newer rat model of STZ diabetes mellitus has been reported using suitable doses of nicotinamide against the β-cytotoxic effect of STZ. The diabetic syndrome developed in adult rats by injecting nicotinamide and STZ, reported to exhibit comparable features with human Type 2 diabetes mellitus. The literature reveals that sulfonlureas and sodium tungstate are effective in this model. The nicotinamide-STZ model is further validated in mini pigs, in which the glucagon-like peptide-1 derivative NN 2211 has been reported to be effective. However, the optimal dose of nicotinamide to cause a stable hyperglycemia is a major concern with this model.¹⁷⁻¹⁹

**Suggested mechanism of STZ:** Although the exact mechanism of its toxicity is still a matter of debate, one proposed site of action of STZ is at nuclear DNA. During the decomposition of STZ, highly reactive carbonium ions are formed, which cause alkylation of DNA bases¹³ and also STZ may damage the β cell membrane and break the DNA strand which leads to the activation of poly (ADP-ribose) synthetase and NAD depletion, which ultimately leads to cell death (Figure 1).²⁰,²¹

Neonatal STZ-induced rat (n-STZ) model of Type 2 diabe-
tes mellitus: The diabetic syndrome in this model is generated
The 2STZ models are developed by 80 mg/kg, intravenously (sapheneous vein) or intraperitoneally with 100 mg/kg of STZ.\textsuperscript{15} Also, the n-STZ rat model is developed by varying the day of the STZ injection after the birth, such as 2\textsuperscript{nd} day or 5\textsuperscript{th} day of the birth, and these are alternatively called n2-STZ and n5-STZ models respectively.\textsuperscript{22,23}

The n0-STZ model: The rats treated with STZ on the day of birth, exhibit insulin deficient acute diabetes mellitus 3-5 days after birth. They showed high plasma glucose and about 93\% decrease in plasma insulin and high plasma glucagon content. The hyperglycemia observed in the neonates following STZ is only transient.\textsuperscript{21,25} It is reported that the neonatal rats are resistant to STZ.\textsuperscript{15,25,26} The plasma glucose and insulin values are no longer significantly different from those of controls. It was found that only by 8 weeks of age and thereafter n0-STZ rats showed mild hyperglycemia.\textsuperscript{23,24}

Other n-STZ models: As discussed, the n2-STZ and n5-STZ models are developed by 80 mg/kg, i.p. STZ injection on the 2\textsuperscript{nd} day and 5\textsuperscript{th} day of the birth respectively.\textsuperscript{21,25} An interesting variant of the model has been reported: Sprague-Dawley pups were injected intraperitoneally on the 2\textsuperscript{nd} day after birth with 90 mg/kg STZ and on 1.5 days after birth with 120 mg/kg STZ.\textsuperscript{23,24} By 6 weeks of age these animals showed basal hyperglycemia and abnormal glucose tolerance.\textsuperscript{26,27}

The n0-STZ and n2-STZ Wistar models are found almost similar with respect to growth, basal plasma glucose, insulin levels, lack of insulin release in response to glucose or amino acids.\textsuperscript{25} In the insulin secretion studies of the 10-16 week-old n0-STZ rats, there was a complete loss of \(\beta\) cell sensitivity to glucose.\textsuperscript{25} The insulin pulse amplitude was also affected by mild to moderate \(\beta\) cell damage induced by STZ.\textsuperscript{26,27} The impairment of glucose-induced insulin release in n-STZ rat is clearly related to a defect in oxidative glycosis. This leads to a severe decrease in the mitochondrial oxidative catalabolism of glucose-derived pyruvate. It coincides with a lower ATP/ADP ratio in simulated islets and their subsequent alteration of ionic events rightly coupled to the fuel function of the hexose in the islet cells.\textsuperscript{27} It has been found that the n-STZ rats exhibited an increased amylin-insulin molar ratio. This has been identified as a major component of amyloid deposits in the pancreatic islets of patients with Type 2 diabetes mellitus.\textsuperscript{28,29}

Defects in n-STZ models: Adult n0-STZ rats are characterized by a low insulin release in vivo in response to glucose or amino acids.\textsuperscript{25} In the insulin secretion studies of the 10-16 week-old n0-STZ rats, there was a complete loss of \(\beta\) cell sensitivity to glucose.\textsuperscript{25} The insulin pulse amplitude was also affected by mild to moderate \(\beta\) cell damage induced by STZ.\textsuperscript{26,27} The impairment of glucose-induced insulin release in n-STZ rat is clearly related to a defect in oxidative glycosis. This leads to a severe decrease in the mitochondrial oxidative catalabolism of glucose-derived pyruvate. It coincides with a lower ATP/ADP ratio in simulated islets and their subsequent alteration of ionic events rightly coupled to the fuel function of the hexose in the islet cells.\textsuperscript{27} It has been found that the n-STZ rats exhibited an increased amylin-insulin molar ratio. This has been identified as a major component of amyloid deposits in the pancreatic islets of patients with Type 2 diabetes mellitus.\textsuperscript{28,29}

Defects in exocrine pancreas in n-STZ rats: After STZ injection, the pups showed an increase in pancreatic weight and pancreatic protein and DNA content at Day 16 as compared to the control groups, but not thereafter. After Day 16 of the STZ treatment, the n-STZ pups showed a transient increase in their pancreatic lipase and trypsinogen concentration in contrast to pancreatic amylase. The amylase levels were found lowered in STZ pups from Day 18 to Day 42. But the difference between groups was statistically significant only from Days 18 to 24. Insulin supplementation of STZ pups for fewer days in the neonatal period restored the pancreatic amylase concentration to the control level at Days 18-20. This indicated that acute STZ administration at birth to neonates affects subsequent exocrine pancreas development, particularly that of amylase while exogenous insulin attenuated the effect.\textsuperscript{31}

\(\beta\) cell regeneration in n-STZ rats: It has been reported that after the n0-STZ injection, from the postnatal Day 4 onwards, signs of regeneration are apparent, in that numerous insulin positive cells are found throughout the acinar parenchyma and within the duct epithelium, but in 4-month-old animals the regeneration process was incomplete.\textsuperscript{15,23,26} The timing of the STZ injection is the critical factor for the efficiency of the regeneration process, which coincides with the normal development of islet cell mass in the rat.\textsuperscript{31}
The n5-STZ rats showed lack of significant re-accumulation of insulin in the pancreas after 2 weeks following the β cell insult, but some degree of recovery in the insulin stores was found in the pancreas of the n2-STZ and n0-STZ rats. It has been proved that there is some capacity of β cell regeneration in the neonatal rat pancreas (which is lacking in the adult rodents) and the capacity of the β cell regeneration in the Wistar strain decreases quickly during the first postnatal week and thereafter it is no longer significant.23-26 It is also explained that the regeneration of the β cells in the Sprague-Dawley neonates is less efficient than in the Wistar strain. The recovery from diabetes mellitus in the Sprague-Dawley n2-STZ model is due to the partial replenishment of the β cell mass from the replication of the existing β cells, rather than neogenesis from undifferentiated precursors.31,35

n-STZ Type 2 diabetes mellitus: Is it reversible?

It has been reported that after a STZ-induced injury, the surviving β cells are able to maintain most of their metabolic functions but fail to maintain an adequate insulin production.23-25 When the n0-STZ model is included for insulin therapy, the basal glucose levels are decreased, but the pancreatic insulin stores are not affected by the insulin therapy, this needs a minimum of 5 days of insulin therapy.36 It is hypothesized that the chronic hyperglycemia-hypoinsulinemia in the n0-STZ rat causes abnormal glucose influence on the glucose and arginine-stimulated insulin release.36 In the Sprague-Dawley n2-STZ model the defects of glucose-induced insulin secretion were not restored by insulin treatment.26,27 It is noteworthy to recognize that the efforts to restore glucose-induced first phase insulin release in humans with Type 2 diabetes mellitus have not been totally successful.26,28

Interestingly, insulin therapy corrected the insulin response to glucose in the n0-STZ rat model, supporting the view that mild hyperglycemia and hypoinsulinemia contribute to the defective insulin response to glucose.22

Insulin resistance in n-STZ models

There are evidences that a severe reduction in the β cells obtained from subjects with Type 2 diabetes mellitus or animals after STZ injection is associated with no severe insulin resistance.36 It is found that the induction of insulin resistance in an individual with reasonably normal islet function leads to modest elevation of the plasma glucose level, whereas in an individual with impaired islet cell functions it leads to hyperglycemia.29

In contrast to the above findings, in 8-week-old n0-STZ female rats, it was shown that hepatic glucose production measured in the basal state was higher in the diabetes mellitus models than in the controls, despite similar peripheral insulin levels in both groups.22 It is found that in white and brown adipose tissues, an increased responsiveness to insulin action is detected when comparing diabetic females to control females and insulin action was found normal in the skeletal muscles and diaphragm of the same adult females. The observations of the hormonal insulin action in the liver and white and brown adipose tissues indicated that glucose is preferentially channeled towards the liver and adipose tissue in n0-STZ females. The clamp studies in the n5-STZ model showed that the glucose utilization by the whole body mass induced by hyperinsulinenia was significantly reduced and the hepatic glucose production rate was less efficiently suppressed by submaximal or maximal insulin levels, which indicated that the insulin resistance is present in vivo at the level of the peripheral tissues and the liver.36-38 As discussed, this confirmed that when β cell insult is the primary factor responsible for the emergence of moderate to severe hyperglycemia in rats, insulin resistance can develop secondarily39-41 and a certain degree of insulin deficiency is necessary to induce insulin resistance.42-43

Is n-STZ rat a better model of Type 2 diabetes mellitus?

By altering the dose and the day of the STZ injection, the n-STZ models exhibit various stages of Type 2 diabetes mellitus, such as impaired glucose tolerance, mild, moderate and severe hyperglycemia. The n-STZ rats exhibit slightly lowered plasma insulin levels, slightly elevated plasma glucose levels and lowered pancreatic insulin content.40,41 The β cells in the n-STZ rats bear a resemblance to the insulin secretory characteristics found in Type 2 diabetic patients (Table 1).22,42-48

The pattern of insulin release found in the n0-STZ and n2-STZ rats is qualitatively similar to that of the GK (Goto-Kakizaki) rat, which is a genetically diabetic non-obese model of human diabetes mellitus.47

Conclusion

It is understood that no animal model is identical to any human syndrome: none of the available animal models of Type 2 diabetes mellitus exactly simulate the human Type 2 diabetes mellitus. However, n-STZ rat models have several advantages over the other models as described above and is considered to be one of the suitable experimental animal models of Type 2 diabetes mellitus.

Acknowledgements

The authors wish to thank Dr. S. K. Arora, President, Lupin Research Park, Pune

Table 1

Comparison of features/characteristics of human Type 2 diabetes and n-STZ diabetic animals

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Human Type 2 diabetes</th>
<th>n-STZ diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreatic insulin</td>
<td>++</td>
<td>+ / -</td>
</tr>
<tr>
<td>Basal plasma glucose</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td>Basal plasma insulin</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Glucose tolerance</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Insulin tolerance</td>
<td>++</td>
<td>- / +</td>
</tr>
<tr>
<td>Obesity</td>
<td>- / +</td>
<td>-</td>
</tr>
<tr>
<td>Diabetic complications</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

' + ' = Present; ' - ' = Absent
References


41. Trent PF, Fletneer DJ, May JM, Bonnier-Wir SGC. Abnormal islet and adipocyte function in young β cell deficient rats with normoglycemia. Diabetes 1984;33:170-5.


